Apelin retards the progression of diabetic nephropathy

American Journal of Physiology - Renal Physiology

Volumn 304, Issue 6, 2013, Pages

  Day, Robert T ^a   Cavaglieri, Rita C ^a   Feliers, Denis ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Apelin; Diabetes; Inflammation; Nephropathy

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; APELIN; CATALASE; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; VASCULAR CELL ADHESION MOLECULE 1; ANGIOTENSIN RECEPTOR; APLN PROTEIN, MOUSE; APLNR PROTEIN, MOUSE; G PROTEIN COUPLED RECEPTOR; SIGNAL PEPTIDE;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CELL INFILTRATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DOWN REGULATION; GLOMERULUS; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BLOOD VESSEL; KIDNEY HYPERTROPHY; MALE; MONOCYTE; MOUSE; NEPHRITIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UPREGULATION; ANIMAL; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; HYPERTROPHY; KIDNEY; METABOLISM; PATHOLOGY;

ALBUMINURIA; ANIMALS; CATALASE; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HYPERTROPHY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; MALE; MICE; MONOCYTES; NEPHRITIS; RECEPTORS, ANGIOTENSIN; RECEPTORS, G-PROTEIN-COUPLED;

MLCS; MLOWN;

EID: 84877929948     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00306.2012     Document Type: Article

References (67)

1. American Diabetes Association. Position statement: diabetic nephropathy. Diabetes Care 24: S69-S72, 2001.
2. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Reno-protective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 57: 601-606, 2000.
3. Ashley E, Chun HJ, Quertermous T. Opposing cardiovascular roles for the angiotensin and apelin signaling pathways. J Mol Cell Cardiol 41: 778-781, 2006.
4. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 40: 405-412, 1991.
5. Chen MM, Ashley EA, Deng DX, Tsalenko A, Deng A, Tabibiazar R, Ben-Dor A, Fenster B, Yang E, King JY, Fowler M, Robbins R, Johnson FL, Bruhn L, McDonagh T, Dargie H, Yakhini Z, Tsao PS, Quertermous T. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 108: 1432-1439, 2003.
6. Daviaud D, Boucher J, Gesta S, Dray C, Guigne C, Quilliot D, Ayav A, Ziegler O, Carpene C, Saulnier-Blache JS, Valet P, Castan-Laurell I. TNFa upregulates apelin expression in human and mouse adipose tissue. FASEB J 20: 1528-1530, 2006.
7. Day RT, Cavaglieri Rde C, Tabatabaimir H, Mantravadi V, Lee MJ, Barnes JL, Kasinath BS, Feliers D. Acute hyperglycemia rapidly stimulates VEGF mRNA translation in the kidney. Role of angiotensin type 2 receptor (AT2). Cell Signal 22: 1849-1857, 2010.
8. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329: 977-986, 1993.
9. Domingues I, Rino J, Demmers JA, de Lanerolle P, Santos SC. VEGFR2 translocates to the nucleus to regulate its own transcription. PLos One 6: e25668, 2011.
10. El-Shehaby AM, El-Khatib MM, Battah AA, Roshdy AR. Apelin: a potential link between inflammation and cardiovascular disease in end stage renal disease patients. Scand J Clin Lab Invest 70: 421-427, 2010.
11. Falcao-Pires I, Goncalves N, Gavina C, Pinho S, Teixeira T, Moura C, Amorim MJ, Pinho P, Areias JC, Leite-Moreira A. Correlation between plasma levels of apelin and myocardial hypertrophy in rats and humans: possible target for treatment? Expert Opin Ther Targets 14: 231-241, 2010.
12. Falcao-Pires I, Goncalves N, Henriques-Coelho T, Moreira-Goncalves D, Roncon-Albuquerque R Jr, Leite-Moreira AF. Apelin decreases myocardial injury and improves right ventricular function in monocrota-line-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol 296: H2007-H2014, 2009.
13. Falcao-Pires I, Ladeiras-Lopes R, Leite-Moreira AF. The apelinergic system: a promising therapeutic target. Expert Opin Ther Targets 14: 633-645, 2010.
14. Feliers D, Kasinath BS. Mechanism of VEGF expression by high glucose in proximal tubule epithelial cells. Mol Cell Endocrinol 314: 136-142, 2010.
15. Flyvbjerg A, Mogensen CE, Osterby R, Orskov H. Renal hypertrophy in experimental diabetes. J Diabetes Complications 5: 62-64, 1991.
16. Fornoni A, Ijaz A, Tejada T, Lenz O. Role of inflammation in diabetic nephropathy. Curr Diabetes Rev 4: 10-17, 2008.
17. Foussal C, Lairez O, Calise D, Pathak A, Guilbeau-Frugier C, Valet P, Parini A, Kunduzova O. Activation of catalase by apelin prevents oxidative stress-linked cardiac hypertrophy. FEBS Lett 584: 2363-2370, 2010.
18. Fukushima H, Kobayashi N, Takeshima H, Koguchi W, Ishimitsu T. Effects of olmesartan on apelin/APJ and Akt/endothelial nitric oxide synthase pathway in Dahl rats with end-stage heart failure. J Cardiovasc Pharmacol 55: 83-88, 2010.
19. Gekle M. Renal tubule albumin transport. Annu Rev Physiol 67: 573-594, 2005.
20. Giani JF, Burghi V, Veiras LC, Tomat A, Munoz MC, Cao G, Turyn D, Toblli JE, Dominici FP. Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats. Am J Physiol Renal Physiol 302: F1606-F1615, 2012.
21. Gundersen HJ, Mogensen CE, Seyer-Hansen K, Osterby R, Lund-baek K. Early and late changes in the diabetic kidney. Adv Nephrol Necker Hosp 8: 43-62, 1979.
22. Ha H, Kim KH. Role of oxidative stress in the development of diabetic nephropathy. Kidney Int Suppl 51: S18-21, 1995.
23. Hwang I, Lee J, Huh JY, Park J, Lee HB, Ho YS, Ha H. Catalase deficiency accelerates diabetic renal injury through peroxisomal dysfunction. Diabetes 61: 728-738, 2012.
24. Iademarco MF, McQuillan JJ, Rosen GD, Dean DC. Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1). J Biol Chem 267: 16323-16329, 1992.
25. Israel A. The IKK complex: an integrator of all signals that activate NF-kB? Trends Cell Biol 10: 129-133, 2000.
26. Iwanaga Y, Kihara Y, Takenaka H, Kita T. Downregulation of cardiac apelin system in hypertrophied and failing hearts: Possible role of angiotensin II-angiotensin type 1 receptor system. J Mol Cell Cardiol 41: 798-806, 2006.
27. Kakkar R, Mantha SV, Radhi J, Prasad K, Kalra J. Antioxidant defense system in diabetic kidney: a time course study. Life Sci 60: 667-679, 1997.
28. Kedziora-Kornatowska K. Effect of angiotensin convertase inhibitors and AT1 angiotensin receptor antagonists on the development of oxidative stress in the kidney of diabetic rats. Clin Chim Acta 287: 19-27, 1999.
29. Kidoya H, Naito H, Takakura N. Apelin induces enlarged and nonleaky blood vessels for functional recovery from ischemia. Blood 115: 3166-3174, 2010.
30. Kohzuki M, Yasujima M, Kanazawa M, Yoshida K, Fu LP, Obara K, Saito T, Abe K. Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats. J Hypertens 13: 97-103, 1995.
31. Leeper NJ, Tedesco MM, Kojima Y, Schultz GM, Kundu RK, Ashley EA, Tsao PS, Dalman RL, Quertermous T. Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation. Am J Physiol Heart Circ Physiol 296: H1329-H1335, 2009.
32. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angioten-sin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462, 1993.
33. Liu W, Yu WR, Carling T, Juhlin C, Rastad J, Ridefelt P, Akerstrom G, Hellman P. Regulation of gp330/megalin expression by vitamins A and D. Eur J Clin Invest 28: 100-107, 1998.
34. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 7: 684-696, 2011.
35. Malyszko J, Malyszko JS, Pawlak K, Wolczynski S, Mysliwiec M. Apelin, a novel adipocytokine, in relation to endothelial function and inflammation in kidney allograft recipients. Transplant Proc 40: 3466-3469, 2008.
36. Marshall SM. The podocyte: a major player in the development of diabetic nephropathy? Hormone and metabolic research. Hormon Stoffwechselforschung 37, Suppl 1: 9-16, 2005.
37. Menke A, Geerling I, Giehl K, Vogelmann R, Reinshagen M, Adler G. Transforming growth factor- fj-induced upregulation of transforming growth factor-p receptor expression in pancreatic regeneration. Biochim Biophys Acta 1449: 178-185, 1999.
38. Meral C, Tascilar E, Karademir F, Tanju IA, Cekmez F, Ipcioglu OM, Ercin CN, Gocmen I, Dogru T. Elevated plasma levels of apelin in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 23: 497-502, 2010.
39. Mezzano S, Aros C, Droguett A, Burgos ME, Ardiles L, Flores C, Schneider H, Ruiz-Ortega M, Egido J. NF-kB activation and overex-pression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 19: 2505-2512, 2004.
40. Miller JA. Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. J Am Soc Nephrol 10: 1778-1785, 1999.
41. Nelson J, Denisenko O, Bomsztyk K. The fast chromatin immunopre-cipitation method. Methods Mol Biol 567: 45-57, 2009.
42. Osterby R. Structural changes in the diabetic kidney. Clin Endocrinol Metab 15: 733-751, 1986.
43. Perkins ND. The Rel/NF-K B family: friend and foe. Trends Biochem Sci 25: 434-440, 2000.
44. Pitkin SL, Maguire JJ, Bonner TI, Davenport AP. International Union of Basic and Clinical Pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function. Pharmacol Rev 62: 331-342, 2010.
45. Rasch R, Norgaard JO. Renal enlargement: comparative autoradiographic studies of 3H-thymidine uptake in diabetic and uninephrectomized rats. Diabetologia 25: 280-287, 1983.
46. Roberts E, Newson M, Pope G, Landgraf R, Lolait S, O'Carroll AM. Abnormal fluid homeostasis in apelin receptor knockout mice. J Endocrinol 202: 453-462, 2009.
47. Schmid H, Boucherot A, Yasuda Y, Henger A, Brunner B, Eichinger F, Nitsche A, Kiss E, Bleich M, Grone HJ, Nelson PJ, Schlondorff D, Cohen CD, Kretzler M. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 55: 2993-3003, 2006.
48. Schwieger J, Fine LG. Renal hypertrophy, growth factors, and nephropathy in diabetes mellitus. Semin Nephrol 10: 242-253, 1990.
49. Seyer-Hansen K. Renal hypertrophy in experimental diabetes mellitus. Kidney Int 23: 643-646, 1983.
50. Seyer-Hansen K. Renal hypertrophy in streptozotocin-diabetic rats. Clin Sci Mol Med Suppl 51: 551-555, 1976.
51. Siddiquee K, Hampton J, Khan S, Zadory D, Gleaves L, Vaughan DE, Smith LH. Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production. J Hypertens 29: 724-731, 2011.
52. Siddiquee K, Hampton J, McAnally D, May LT, Smith LH. The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition. Br J Pharmacol 2012 Aug 31 [Epub ahead of print].
53. Stanton RC. Oxidative stress and diabetic kidney disease. CurrDiab Rep 11: 330-336, 2011.
54. Starkey JM, Haidacher SJ, Lejeune WS, Zhang X, Tieu BC, Choud-hary S, Brasier AR, Denner LA, Tilton RG. Diabetes-induced activation of canonical and noncanonical nuclear factor-Kb pathways in renal cortex. Diabetes 55: 1252-1259, 2006.
55. Takano Y, Minami H, Misake A, Nakabou Y, Hagihira H. A possible role for ribonuclease in the regulation of protein synthesis in relation to kidney growth of diabetic rat. Tokushima J Exp Med 26: 5-12, 1979.
56. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, Kurokawa T, Onda H, Fujino M. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 251: 471-476, 1998.
57. Thabard W, Collette M, Mellerin MP, Puthier D, Barille S, Bataille R, Amiot M. IL-6 upregulates its own receptor on some human myeloma cell lines. Cytokine 14: 352-356, 2001.
58. Thomas MC. Pathogenesis and progression of proteinuria. Contrib Nephrol 170: 48-56, 2011.
59. Tojo A, Onozato ML, Ha H, Kurihara H, Sakai T, Goto A, Fujita T, Endou H. Reduced albumin reabsorption in the proximal tubule of early-stage diabetic rats. Histochem Cell Biol 116: 269-276, 2001.
60. Tuomilehto J, Borch-Johnsen K, Molarius A, Jormanainen V, Lou-namaa R, Gronhagen-Riska C, Reunanen A, Sarti C. The unchanging incidence of hospitalization for diabetic nephropathy in a population-based cohort of IDDM patients in Finland. Diabetes Care 20: 1081-1086, 1997.
61. Viatour P, Merville MP, Bours V, Chariot A. Phosphorylation of NF-kB and IkB proteins: implications in cancer and inflammation. Trends Biochem Sci 30: 43-52, 2005.
62. Visser YP, Walther FJ, Laghmani el H, Laarse A, Wagenaar GT. Apelin attenuates hyperoxic lung and heart injury in neonatal rats. Am J Respir Crit Care Med 182: 1239-1250, 2010.
63. Wei SG, Yu Y, Zhang ZH, Felder RB. Angiotensin II upregulates hypothalamic AT1 receptor expression in rats via the mitogen-activated protein kinase pathway. Am J Physiol Heart Circ Physiol 296: H1425-H1433, 2009.
64. Wu J, Guan TJ, Zheng S, Grosjean F, Liu W, Xiong H, Gordon R, Vlassara H, Striker GE, Zheng F. Inhibition of inflammation by pentosan polysulfate impedes the development and progression of severe diabetic nephropathy in aging C57B6 mice. Lab Invest 91: 1459-1471, 2011.
65. Yang L, Brozovic S, Xu J, Long Y, Kralik PM, Waigel S, Zacharias W, Zheng S, Epstein PN. Inflammatory gene expression in OVE26 diabetic kidney during the development of nephropathy. Nephron Exp Nephrol 119: e8-e20, 2011.
66. Zeng XJ, Zhang LK, Wang HX, Lu LQ, Ma LQ, Tang CS. Apelin protects heart against ischemia/reperfusion injury in rat. Peptides 30: 1144-1152, 2009.
67. Zheng S, Noonan WT, Metreveli NS, Coventry S, Kralik PM, Carlson EC, Epstein PN. Development of late-stage diabetic nephropathy in OVE26 diabetic mice. Diabetes 53: 3248-3257, 2004.